{
  "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
  "docSlug": "6d3545a6c010d7cb",
  "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
  "authorId": "GoldmanSachs",
  "authorName": "EyePoint Pharmaceuticals",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 16,
  "pageCount": 29,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "comparison_table",
  "function": "compare_options",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "The slide uses a timeline-based visual to contrast injection frequency across five different pharmaceutical products.",
  "elementsJson": [
    "headline_text",
    "process_diagram",
    "icon_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/16",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.74
      },
      "kind": "callout",
      "text": "DURAVYU 6-month dosing",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd20d52a-826d-473b-b97a-4c24f9587d30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.94,
        "x": 0.03,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Visual comparison of injection frequency over 24 months for Eylea, Eylea HD, Lucentis, Vabysmo, and Duravyu.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a44da22-a238-4ad2-9d33-d040db1e1ee7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Dosing frequency: 6-month",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-1d6c-779c-a620-106237bdf9e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.44,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "*Potential positioning for DURAVYU, if approved, based on Phase 3 protocol for wet AMD. SoC, standard of care",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dfca600e-32ab-4392-b5cf-280b938fa205",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "DURAVYU is Uniquely Positioned to Provide an Improved DME Treatment Paradigm Compared to Current Anti-VEGF Therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfefaedf-9cb0-4347-946e-edf8368643b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "title",
      "text": "24-Month Treatment Regimens for DME:",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c802e0b-2b8e-4d93-a391-76409a276634",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "d4b93a89-50cc-4a06-9358-0c169fc73e80",
      "evidence": "Visual representation of treatment frequency over a 24-month period.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}